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9 Abstract The levels of expression of the four receptors
10 and eleven ligands composing the epidermal growth factor
11 family were measured using immunohistochemical staining
12 in one hundred cases of breast cancer. All of the family
13 were expressed to some degree in some cases; however,
14 individual cases showed a very wide range of expression of
15 the family from essentially none to all the factors at high
16 levels. The highest aggregate level of expression of a
17 receptor was HER2 followed by HER1, then HER3, then
18 HER4. The ligands (including two splice variants of the
19 NRG1 and NRG2 genes) broadly fell into three groups,
20 those with the highest aggregate expression were Epigen,
21 Epiregulin, Neuregulin 1a, Neuregulin 2a, Neuregulin 2b,
22 Neuregulin 4 and TGFa, moderate expression was seen
23 with EGF, Neuregulin 1b and Neuregulin 3, and relatively
24 low levels of expression were seen of HB-EGF, Betacell-
25 ulin and Amphiregulin. Statistical analysis using Spear-
26 man’s Rank Correlation showed a positive correlation of
27 expression between each of the factors. Analysing the data
28 using the Cox Proportional Hazards model showed that, in
29this dataset, the most powerful predictors of relapse free
30interval and overall survival were the combined measure-
31ment of only Epigen and Neuregulin 4.
32
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34Growth factor receptor  Prognosis  Breast cancer
35Introduction
36The epidermal growth factor family of receptors and
37ligands consist of four genes encoding receptors and at
38least eleven genes encoding ligands [1]. Four of the
39ligands, collectively known as the Neuregulins, are
40expressed as multiple splice variants [2] and the latest
41receptor to be discovered, HER4, is made in at least four
42different forms also due to mRNA splicing [3]. The
43receptors are stabilised in an active state as homodimers or
44heterodimers following ligand binding [4]. Exactly, which
45forms are assembled in vivo is contingent on the repertoire
46of ligands available in the environment and their relative
47affinities for each receptor type individually and possibly
48for preferences for binding to particular dimer pairs. We
49have attempted previously to construct a computer simu-
50lation of this process [5] (http://www.cs.kent.ac.uk/people/
51rpg/em84/CellApplet1.html) in which a patch of cell
52membrane can be populated with different numbers of each
53receptor type and each of the eleven ligands can be intro-
54duced to initiate the assembly of the various receptor
55pairwise combinations. This when run to equilibrium
56should resemble the state of the system in a simple mem-
57brane bilayer.
58Overexpression of most, if not all, of the receptors and
59some of the ligands has been detected in breast cancer
60biopsies and cell lines. Antibodies or small molecule
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61 tyrosine kinase inhibitors have been evaluated targeted to
62 members of the system and some of these have been
63 introduced as clinical treatments for selected patients with
64 some success [6]. It would be helpful, however, to under-
65 stand and predict the activation state of the system in
66 individual patients so that the choice of the available
67 inhibitors can be most precisely made to ensure that
68 appropriate drugs are given and that those that are used can
69 be employed most cost-effectively.
70 Despite nearly 50 years of research and a long term
71 appreciation of the potential importance of this family of
72 molecules in breast and other cancer types as yet there has
73 been no study published to our knowledge that described
74 the expression patterns of the complete family of receptors
75 and ligands in breast cancers at the protein level. Indeed
76 some of the more recently described ligands such as Epigen
77 [7] and Epiregulin [8] have not so far been studied in a
78 series of clinical specimens. We report here using immu-
79 nohistochemical staining a study describing the complete
80 family in one hundred cases of unselected breast cancers.
81 Materials and methods
82 One hundred cases of breast cancer were obtained from
83 Professor Adrian Harris and Dr Russell Leek, Cancer
84 Research UK, Oxford, UK in the form of a tissue array.
85 Ethical approval for use was obtained from Oxfordshire
86 Clinical Research Ethics Committee. The patients were
87 treated by standard protocols, which were updated regu-
88 larly according to national guidelines. ER positive patients
89 received tamoxifen for 5 years, node positive patients
90 under 60 also received 6 cycles of intravenous CMF.
91 Patients treated with wide local excision also received
92 adjuvant radiation therapy. The composition of the patients
93 is described in Supplementary Table 1 including age range,
94 grade, tumour size, ER status, node status, menopausal
95 status, whether treated by chemotherapy or hormonal
96 therapy and follow up. The study was conducted and
97 reported cohering to the guidelines published in McShane,
98 LM, et al. Reporting recommendations for tumour marker
99 prognostic studies. J Clin Oncol. 2005 Dec 20; 23(36):
100 9067–9072.
101 The antibodies used were mostly produced in the labo-
102 ratory of Professor Gullick (Table 1). The antibody to EGF
103 was a kind gift of the late Dr Harry Gregory. The anti-
104 bodies to Epigen (Catalogue number AF1127) and to
105 Epiregulin (Catalogue number AF1195) were purchased
106 from R&D Systems, Minneapolis, USA and the antibody to
107 TGFalpha (Catalogue number GF10) from Calbiochem,
108 San Diego, USA. Immunohistochemical staining was per-
109 formed using the primary antibodies described earlier and
110 the StreptABCcomplex HRP Duet Mouse/Rabbit detection
111kit from Dako, Denmark. For detection of Epigen and
112Epiregulin rabbit anti-goat biotinylated IgG (Dako) was
113used with the kit. Optimisation of the concentration of each
114antibody was performed prior to its use on the tissue arrays.
115Tumours were scored for intensity of staining by inspection
116on an Olympus BX40 microscope with a ‘‘double head’’ by
117WJG and EM using a scale of 0 = negative, 1 = weak,
1182 = moderate and 3 = strong.
119Results
120Each antibody detected specifically its cognate protein in a
121proportion of cases. Results with antibodies to Epigen and
122Epiregulin, which have not previously been measured in
123breast cancer, are shown in Fig. 1a and b. In order to assess
124the overall expression levels for each protein we summed
125the scores for the hundred cases. The highest aggregate
126score for the four receptors was for HER2. It should be
127noted that this does not reveal heterogeneity of expression
128between cases, for instance many previous studies have
129reported that about 20% of breast cancers score 3? for
130HER2 but this would not be apparent in this analysis.
131However, it does demonstrate, in particular with the
132ligands, some of which have not previously been studied,
133that there are broad categories of expression present.
134Highest scoring ligands included Epigen, Epiregulin,
135Neuregulin 1a, Neuregulin 2a, Neuregulin 2b, Neuregulin
1364 and TGFa, moderate expression was seen with EGF,
137Neuregulin 1b and Neuregulin 3 and low levels of
138expression were seen of HB-EGF, Betacellulin and
139Amphiregulin.
Table 1 Antibodies used in this study
EGF receptor F4 Mouse mAb Gullick et al. [9]
HER2 21 N Rabbit polyclonal Gullick et al. [10]
HER3 RTJ2 Mouse mAb Rajkumar et al. [11]
HER4 HFR1 Mouse mAb Srininvasan et al. [12]
EGF Rabbit polyclonal From H Gregory
TGFalpha GF10 Mouse mAb CalBiochem
Amphiregulin 55AR Rabbit polyclonal Saeki et al. [13]
HB-EGF 111HB Rabbit polyclonal Chobotava et al. [14]
Epigen AF1127 Goat polyclonal R&D Systems
Epiregulin AF1195 Goat Polyclonal R&D Systems
Betacellulin 97BTC Rabbit polyclonal Srinivasan et al. [15]
NRG1a 76HRG Rabbit polyclonal Normanno et al. [16]
NRG1b 102HRG Rabbit polyclonal Srinivasan et al. (15)
NRG2a 121NRG Rabbit polyclonal Dunn et al. [17]
NRG2b 120NRG Rabbit polyclonal Dunn et al. [17]
NRG3 122NRG3 Rabbit polyclonal Dunn et al. [17]
NRG4 123NRG4 Rabbit polyclonal Dunn et al. [17]
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140 The data obtained was analysed for any associations
141 between expression of each ligand and receptor with each
142 of the others using Spearman’s Rank Correlation. From the
143 data in Fig. 2a, it can be seen that all the ligands and
144 receptors were positively associated. To provide a visual
145 representation of this large dataset, we have shown the
146 cases ordered on the ordinate in ascending score for total
147 ligands (Fig. 2b, left axis, range 0–33) and shown the total
148 receptor score (range 0–12, right axis). The data reveal a
149 strong association between increasing total ligand score
150 and increasing total receptor score. It is also apparent that
151 there are some cases that essentially lack any receptor or
152 ligand expression at the cut of value scored while other
153 cases showed high levels of almost all the ligands and
154 receptors suggesting very great heterogeneity in the pres-
155 ence of this highly interactive family of signalling mole-
156 cules between individual cases.
157 In order to assess the relationship between the expres-
158 sion of the ligands and receptors and clinical and molecular
159 variables, the tumours were divided in three ways. First,
160 they were dichotomised by low and high ligand levels;
161 second, by low and high receptor levels and finally, by low
162 and high aggregate ligand and receptor levels. No signifi-
163 cant associations were found although the strongest rela-
164 tionship was between receptor levels and tumour size
165 (P = 0.06) (Supplementary Table 2).
166 Kaplan–Meier curves for overall survival (OS) were
167 generated for all the receptors and ligands based on lack of
168expression (0) or any level of expression (1–3) (Fig. 3).
169Several of the factors have not previously been studied in
170breast cancer and thus the dichotomisation of the data was
171chosen to ensure as far as possible similar numbers of cases
172in each category. HER2 expression would normally be
173divided into low (0–2) versus high (3) as this has been
174shown previously to give the best discrimination between
175good and poor survival but it was considered more
176appropriate in this study to maintain consistency within the
177analysis. HER2 was separately analysed as a single factor
178as low (0–2) versus high (3) and, as expected, high
179expression was associated with reduced OS. Analysis of
180the survival data using Cox’s Proportional Hazards model
181identified Epigen and Neuregulin 4 as the factors most
182strongly associated with OS.
183Interestingly, expression of Epigen was positively
184associated with improved survival, and NRG expression
185was associated with worse OS. Various laboratory studies
186have shown that different activation states of the EGF
187family may induce either growth or differentiation and thus
188in the light of our still imperfect knowledge of the system it
189is not unexpected that some factors may have opposite
190effects. In further analysis using the model omitting
191sequentially the weakest factor (backwards elimination
192dropping the factor with the smallest positive or negative
193coefficient), the combination of Epigen (P = 0.003) and
194NRG4 (P = 0.01) retained the strongest association with
195OS (Table 2). In order to assess the influence of these
Fig. 1 Example of
immunostaining of a case of
breast cancer with the antibody
to Epiregulin (a) and Epigen
(b). c Aggregate scores of the
ligands and receptors
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196 factors in a more molecularly homogeneous group of cases
197 and to see if there were any major effects of treatment, the
198 oestrogen receptor positive cases were analysed separately.
199 Again positive expression of Epigen was associated with
200 good OS (P = 0.0092), but NRG2a became the other
201 predictive factor (P = 0.0057). The dataset was only
202 hundred cases (although 1,700 data points were acquired
203 for the 17 factors measured) and further studies on larger
204datasets would be required to confirm or refute these
205apparent relationships.
206Discussion
207Each ligand and each receptor were expressed at a range of
208levels in a proportion of cases of breast cancer in this study.
AR Tgf α BTC Epireg Epigen Nrg4 Nrg3 Nrg2 β Nrg2 α Nrg1 β Nrg1α HB-Egf Egf ErbB4 ErbB3 ErbB2
EGFR 0.42 0.70 0.38 0.28 0.40 0.50 0.64 0.59 0.50 0.67 0.64 0.51 0.67 0.60 0.59 0.66
p-value 5.52E-06 2.20E-16 4.23E-05 0.00244 1.57E-05 3.53E-08 1.76E-13 4.10E-11 5.23E-08 6.25E-15 2.16E-13 2.31E-08 5.24E-15 7.70E-12 3.85E-11 1.78E-14
ErbB2 0.49 0.58 0.42 0.34 0.46 0.62 0.59 0.64 0.62 0.64 0.69 0.44 0.59 0.56 0.51
p-value 8.24E-08 4.40E-11 6.24E-06 0.0002 6.28E-07 2.15E-12 3.70E-11 2.90E-13 1.63E-12 2.38E-13 < 2.2e-16 1.74E-06 3.13E-11 4.24E-10 1.62E-08 
ErbB3 0.41 0.54 0.48 0.33 0.34 0.59 0.51 0.57 0.55 0.59 0.60 0.42 0.59 0.56
p-value 6.89E-06 1.76E-09 1.20E-07 0.00038 0.00023 3.84E-11 1.72E-08 1.44E-10 7.81E-10 2.01E-11 7.85E-12 4.61E-06 3.08E-11 4.65E-10
ErbB4 0.37 0.68 0.38 0.30 0.42 0.63 0.54 0.49 0.65 0.56 0.67 0.37 0.51
p-value 7.41E-05 1.55E-15 3.30E-05 0.00106 4.20E-06 7.32E-13 1.36E-09 5.44E-08 4.84E-14 3.36E-10 4.36E 6.14E-05 1.59E-08
Egf 0.57 0.56 0.56 0.18 0.50 0.54 0.63 0.53 0.57 0.60 0.65 0.61
p-value 1.28E-10 3.38E-10 3.92E-10 0.03666 4.79E-08 1.75E-09 7.38E-13 3.19E-09 2.02E-10 1.21E-11 3.20E-14 5.42E-12
HB-Efg 0.59 0.39 0.65 0.32 0.36 0.53 0.55 0.52 0.47 0.56 0.51
p-value 2.82E-11 1.92E-05 6.35E-14 0.00049 0.00011 4.40E-09 9.64E-10 7.57E-09 2.62E-07 5.27E-10 1.80E-08
Nrg1 α 0.57 0.68 0.54 0.30 0.45 0.67 0.66 0.75 0.65 0.70
p-value 2.40E-10 2.21E-15 2.11E-09 0.00112 6.99E-07 4.77E-16 2.78E-14 2.20E-16 3.31E-14 2.20E-16
Nrg1 β 0.52 0.57 0.53 0.22 0.32 0.60 0.65 0.63 0.54
p-value 1.09E-08 2.12E-10 6.08E-09 0.01355 0.00048 1.11E-11 64304.6 3.90E-13 2.29E-09
Nrg2 α 0.43 0.66 0.51 0.37 0.59 0.70 0.62 0.65
p-value 2.61E-06 1.78E-14 2.44E-08 5.43E-05 4.15E-11 2.20E-16 9.32E-13 7.60E-14
Nrg2 β 0.61 0.59 0.64 0.36 0.51 0.66 0.60
p-value 3.90E-12 2.21E-11 1.28E-13 7.97E-05 1.50E-08 1.18E-14 9.14E-12
Nrg3 0.58 0.58 0.58 0.24 0.50 0.56
p-value 4.72E-11 7.77E-11 8.05E-11 0.0083 5.21E-08 5.01E-10
Nrg4 0.45 0.52 0.51 0.35 0.37
p-value 9.19E-07 8.46E-09 1.62E-08 0.00013 7.14E-05
Epigen 0.32 0.46 0.39 0.46
p-value 0.00056 6.78E-07 1.85E-05 3.75E-07
Epireg 0.26 0.38 0.22







Fig. 2 a Spearman’s rank correlation analysis of all ligands and receptors. b Cases were ordered on the ordinate in increasing ligand score (left)
and associated receptor scores (right)
Fig. 3 Kaplan Meier charts
showing the survival (days) of
the patients based on the level
of expression (0 vs. 1–3) of
Epigen (left) and NRG4 (right)
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209 Statistical analysis of the data revealed a strong associate
210 between the expression of any member of the family and
211 all other members. Although breast cancer is acknowl-
212 edged, both clinically and by analysis of molecular factors,
213 to be a heterogeneous disease it is still perhaps surprising
214 how different the composition of the factors between cases
215 were. In some individuals (at the precision of measurement
216 available from simple immunostaining), there were essen-
217 tially no ligands or receptors present. In other individuals,
218 all the receptors and essentially all the ligands were present
219 at the highest quartile of measurement. This suggests that
220 the family may be, in some cases, relatively unimportant
221 whereas in others it clearly has the potential to be an
222 important influence on cell activity. This may also reflect a
223 sensitivity or lack of sensitivity to drugs designed to inhibit
224 this system.
225 Individual receptors and ligands were, in some cases,
226 associated negatively or positively with shorter relapse free
227 interval or survival. This was not unexpected as some
228 ligands are known to provoke increased rates of cell growth
229 while others appear to stimulate differentiation. Using the
230 Cox’s Proportional Hazards model, we show that a com-
231 bination of Epigen and Neuregulin 4 in this series of cases
232 together gives the greatest separation of aggressive from
233 indolent disease. This result could not be predicted as we
234 are currently unaware of their individual activities in any
235 detail nor their effect on the balance between growth on the
236 one hand and differentiation on the other. It is likely,
237 however, that measuring a subset of the family may allow
238 prediction of the natural history of the disease in some
239 cases. Here two factors emerged, but further test datasets
240would be required to determine whether this was general-
241isable. The Neuregulins are produced as multiple splice
242variants for instance, five have so far been identified as
243products of the NRG4 gene [18] and these have very dif-
244ferent destinations within or without the cell and as such
245may also have different functions. The antibodies used here
246to the ligands (where known) are directed to the EGF-like
247sequence which is shared by all the so far reported splice
248variants and should thus detect the sum of the expressed
249gene products. The use of reagents which can discriminate
250between the splice variants may give a better ability to
251predict their involvement and influence in the disease.
252The use of computer simulations of the EGF system has
253been an area of considerable study as we have a reasonable
254knowledge of its constituents and some understanding of
255how they function. It may be in the future that a ‘‘reading’’
256of the family of receptors and ligands (or a subset of them)
257may be able to more accurately predict prognosis and,
258more importantly, select patients for treatment with par-
259ticular combinations of signal transduction inhibitor drugs.
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